4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
|
|
|
- CAS号:
- 170569-86-5
- 英文名:
- 4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
- 英文别名:
- SC-236;SC-58236;SC 236 - SC 58236;4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL]BENZENESULFONAMIDE;4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE;Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-;SC-236,gastric,PPAR,cancer,ischemia,Liver,inhibit,allodynia,Inhibitor,fibrogenesis,neuroprotection,COX,Cyclooxygenase,Apoptosis,TNF-α,Peroxisome proliferator-activated receptors,fibrosis,SC236
- 中文名:
- 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
- 中文别名:
- 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-;4-(5-(4-氯苯基)-3-(三氟甲基)-1H-吡唑-1-基)苯磺酰胺
- CBNumber:
- CB3243082
- 分子式:
- C16H11ClF3N3O2S
- 分子量:
- 401.79
- MOL File:
- Mol file
|
|
|
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-化学性质
-
熔点:
-
146-148°C
-
|
-
沸点:
-
543.4±60.0 °C(Predicted)
-
|
-
密度:
-
1.54±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
DMSO: >20mg/mL
-
|
-
形态:
-
powder
-
|
-
酸度系数(pKa):
-
9.66±0.10(Predicted)
-
|
-
颜色:
-
white to off-white
-
|
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-性质、用途与生产工艺
SC-236 是具有口服活性的 COX-2 特异性抑制剂 (对 COX-1 的 IC50 值为 10 nM)和 PPARγ 激动剂。SC-236 可通过 c-Jun 氨基端抑制激活蛋白-1 (AP-1) 活性。SC-236在小鼠模型中通过抑制 ERK 的磷酸化发挥抗炎作用。
|
COX-2
10 nM (IC
50
)
|
COX-1
17.8 μM (IC
50
)
|
SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS.
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay.
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage
viability.
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture.
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway.
Western Blot Analysis
|
Cell Line:
|
vECs.
|
|
Concentration:
|
15 μM
|
|
Incubation Time:
|
30 min.
|
|
Result:
|
Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs.
|
Western Blot Analysis
|
Cell Line:
|
COS 7 cells.
|
|
Concentration:
|
3 and 10 μM.
|
|
Incubation Time:
|
18 h (combined with 15d-PGJ
2
).
|
|
Result:
|
Acted in a concentration-dependent manner as a PPARγ agonist.
|
SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals.
|
Animal Model:
|
Seventy-six male adult Wistar rats weighing 200-220 g (CCl
4
-treated).
|
|
Dosage:
|
6 mg/kg.
|
|
Administration:
|
Orally, 3 times per week.
|
|
Result:
|
A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats.
Significantly reduced the degree of liver fibrosis.
Dramatically suppressed α-SMA expression in CCl4-treated rats.
|
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-W010983 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
SC-236 | 170569-86-5 | 5mg | 800元 |
| 2024/01/25 | HY-W010983 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
SC-236 | 170569-86-5 | 10mM * 1mLin DMSO | 880元 |
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
生产厂家
170569-86-5, 4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 相关搜索:
- Pharmaceuticals
- Pfizer compounds
- Intermediates & Fine Chemicals
- Inhibitors
- Heterocycles
- Apoptosis
- Amines
- 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-吡唑-1-基)苯磺酰胺
- 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
- 170569-86-5
- SC-236,gastric,PPAR,cancer,ischemia,Liver,inhibit,allodynia,Inhibitor,fibrogenesis,neuroprotection,COX,Cyclooxygenase,Apoptosis,TNF-α,Peroxisome proliferator-activated receptors,fibrosis,SC236
- SC 236 - SC 58236
- Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
- SC-58236
- 4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL]BENZENESULFONAMIDE
- 4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
- SC-236